SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Privium Fund Management B.V.

CIK 0001795097 · GUSTAV MAHLERPLEIN 3, AMSTERDAM, P7, 1082 MS · 31 20 462 6644

Reported Value
$442M
Q4 2024
Positions
64
Filings on Record
20
2019–present window
Filed
Feb 11, 2025
original filing

Summary

Privium Fund Management B.V. reported $442M in U.S.-listed holdings across 64 positions for Q4 2024.

The portfolio is heavily concentrated: TSLA alone accounts for 20.1% of reported value.

Compared with Q3 2024, the fund opened 10 new positions and exited 28.

Portfolio Metrics

Turnover
+16.2%
vs prior filed quarter
Top-10 Concentration
+74.2%
share of reported value
Largest Position
+20.1%
Tesla
New / Exited
10 / 28
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $504MQ4 ’21Q1 ’22: $452MQ2 ’22: $302MQ3 ’22: $275MQ3 ’22Q4 ’22: $264MQ1 ’23: $298MQ2 ’23: $347MQ2 ’23Q3 ’23: $336MQ4 ’23: $359MQ1 ’24: $374MQ1 ’24Q2 ’24: $392MQ3 ’24: $402MQ4 ’24: $442MQ4 ’24Q1 ’25: $384MQ2 ’25: $464MQ3 ’25: $556MQ3 ’25Q4 ’25: $543MQ1 ’26: $480Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.8%Other: 22.4%ADR: 6.6%Equity WRT: 1.1%ETP: 0.1%
  • Common Stock · 69.8% · $308M
  • Other · 22.4% · $99M
  • ADR · 6.6% · $29M
  • Equity WRT · 1.1% · $5M
  • ETP · 0.1% · $414,226

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SMRNUSCALE PWR CORPNEW+360.0K360.0K+$6M$6M
ARQTARCUTIS BIOTHERAPEUTICS INCNEW+325.7K325.7K+$5M$5M
IONQ/WSIONQ INCNEW+128.0K128.0K+$4M$4M
LXEOLEXEO THERAPEUTICS INCNEW+138.1K138.1K+$908,797$908,797
CMPOWCOMPOSECURE INCNEW+148.9K148.9K+$692,166$692,166
EMXEMX RTY CORPNEW+217.0K217.0K+$375,355$375,355
UROGEN PHARMA LTDNEW+27.7K27.7K+$294,909$294,909
GCM GROSVENOR INCNEW+137.8K137.8K+$173,639$173,639

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TSLATESLA INChistory →COM20.10%$89M220.0K
2SPOTIFY TECHNOLOGY S ASHS14.68%$65M145.0K
3SHOPSHOPIFY INChistory →CL A9.99%$44M415.0K
4AMZNAMAZON COM INChistory →COM7.00%$31M141.0K
5PLTRPALANTIR TECHNOLOGIES INChistory →CL A6.33%$28M370.0K
6SESEA LTDhistory →SPONSORD ADS5.04%$22M210.0K
7PROQR THRAPEUTICS N VSHS EURO2.99%$13M4.99M
8UNIQURE NVSHS2.97%$13M742.2K
9SNOWSNOWFLAKE INChistory →CL A2.62%$12M75.0K
10RAREULTRAGENYX PHARMACEUTICAL INhistory →COM2.46%$11M258.4K
11NVDANVIDIA CORPORATIONhistory →COM2.22%$10M73.0K
12ISIIONIS PHARMACEUTICALS INChistory →COM2.11%$9M266.8K
13ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM1.84%$8M97.2K
14MRKMERCK & CO INChistory →COM1.63%$7M72.6K
15ARWRARROWHEAD PHARMACEUTICALS INhistory →COM1.62%$7M380.6K
16NETCLOUDFLARE INChistory →CL A COM1.46%$6M60.0K
17SMRNUSCALE PWR CORPhistory →CL A COM1.46%$6M360.0K
18AXSMAXSOME THERAPEUTICS INChistory →COM1.19%$5M62.2K
19RCKTROCKET PHARMACEUTICALS INChistory →COM1.13%$5M397.6K
20ZLABZAI LAB LTDhistory →ADR1.10%$5M185.1K
21ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM1.03%$5M325.7K
22IONQ/WSIONQ INC*W EXP 10/01/2020.88%$4M128.0K
23MRNAMODERNA INCCOM0.78%$3M82.5K
24CPNGCOUPANG INCCL A0.71%$3M141.9K
25ACADACADIA PHARMACEUTICALS INCCOM0.62%$3M148.4K
26ROIVANT SCIENCES LTDSHS0.58%$3M215.5K
27ASTSAST SPACEMOBILE INCCOM CL A0.53%$2M111.5K
28MSFTMICROSOFT CORPCOM0.48%$2M5.0K
29KRYSKRYSTAL BIOTECH INCCOM0.33%$1M9.3K
30CRISPR THERAPEUTICS AGNAMEN AKT0.31%$1M35.0K
31MEIRAGTX HLDGS PLCCOM0.31%$1M225.1K
32ABEVAMBEV SASPONSORED ADR0.27%$1M652.4K
33WAVE LIFE SCIENCES LTDSHS0.25%$1M88.0K
34RNAGBPAVIDITY BIOSCIENCES INCCOM0.21%$927,65231.9K
35LXEOLEXEO THERAPEUTICS INCCOM0.21%$908,797138.1K
36ALXOALX ONCOLOGY HLDGS INCCOM0.19%$850,129509.1K
37RXRXRECURSION PHARMACEUTICALS INCL A0.18%$804,440119.0K
38CMPOWCOMPOSECURE INC*W EXP 12/27/2020.16%$692,166148.9K
39FDMT4D MOLECULAR THERAPEUTICS INCOM0.15%$673,970121.0K
40VALARIS LTDCL A0.14%$627,41214.2K
41NOVNOV INCCOM0.14%$626,17942.9K
42AIGAMERICAN INTL GROUP INCCOM NEW0.13%$584,1478.0K
43PFEPFIZER INCCOM0.13%$583,07722.0K
44AUTLAUTOLUS THERAPEUTICS PLCSPON ADS0.12%$544,434231.7K
45DYNDYNE THERAPEUTICS INCCOM0.11%$479,82320.4K
46PAASPAN AMERN SILVER CORPCOM0.10%$430,36221.3K
47SPROTT FDS TRURANIUM MINERS E0.09%$414,22610.3K
48SEA1EURSEABRIDGE GOLD INCCOM0.09%$410,61236.0K
49EMXEMX RTY CORPCOM0.08%$375,355217.0K
50FNVFRANCO NEV CORPCOM0.08%$350,0653.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$480M60May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$543M57Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$556M59Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$464M55Jul 30, 202513F-HRchanges · EDGAR ↗
Q1 2025$384M56May 9, 202513F-HRchanges · EDGAR ↗
Q4 2024$442M64Feb 11, 202513F-HRchanges · EDGAR ↗
Q3 2024$402M82Nov 1, 202413F-HRchanges · EDGAR ↗
Q2 2024$392M129Aug 1, 202413F-HRchanges · EDGAR ↗
Q1 2024$374M117Apr 30, 202413F-HRchanges · EDGAR ↗
Q4 2023$359M114Feb 26, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$336M115Nov 6, 202313F-HRchanges · EDGAR ↗
Q2 2023$347M124Jul 26, 2023RESTATEMENTchanges · EDGAR ↗
Q1 2023$298M126May 3, 202313F-HRchanges · EDGAR ↗
Q4 2022$264M150Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$275M226Nov 3, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M252Jul 28, 202213F-HRchanges · EDGAR ↗
Q1 2022$452M279May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$504M253Feb 9, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.